Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ACP1 | P24666 | 3/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5443785 | 0.82 | MAPT (0.48) | KMT2APOLB | |
| SCHEMBL5443793 | 0.82 | MAPT (0.48) | KMT2APOLB | |
| SCHEMBL5432738 | 0.78 | CHRM3 (0.40) | PTGER4 | |
| SCHEMBL5438392 | 0.78 | CHRM3 (0.40) | PTGER4 | |
| SCHEMBL4968452 | 0.77 | TERT (0.47) | MEN1KMT2AACP1SMARCA2POLB | |
| SCHEMBL4230564 | 0.76 | PTGER4 (0.48) | PTGER4 | |
| SCHEMBL5881693 | 0.76 | ACP1 (0.51) | MEN1KMT2AACP1POLBPTGER4 | |
| SCHEMBL14116635 | 0.74 | TERT (0.44) | BACE1HTR4 | |
| SCHEMBL15774342 | 0.72 | PTGER4 (0.65) | MEN1KMT2APTGER4 | |
| SCHEMBL4069514 | 0.72 | SIGMAR1 (0.44) | MEN1KMT2AACP1SMARCA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | MEN1 3142/4885KMT2A 1921/4885ACP1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.